These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8627878)

  • 1. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder.
    Glick SH; Howell LP; White RW
    J Urol; 1996 May; 155(5):1754-7. PubMed ID: 8627878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
    Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
    Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
    Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ
    Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
    Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
    Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
    Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
    Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
    Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.
    Wu CS; Pollack A; Czerniak B; Chyle V; Zagars GK; Dinney CP; Hu SX; Benedict WF
    Urology; 1996 Mar; 47(3):305-10. PubMed ID: 8633392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
    Wolf HK; Stöber C; Hohenfellner R; Leissner J
    Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
    Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
    J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder.
    Asci R; Yildiz L; Sarikaya S; Buyukalpelli R; Yilmaz AF; Kandemir B
    Urol Int; 2001; 67(1):34-40. PubMed ID: 11464113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
    Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
    Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutation and bcl-2 expression in transitional cell carcinoma of the urinary bladder.
    Wu TT; Lee YH; Huang JK
    Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):9-14. PubMed ID: 11310375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
    Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
    Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcl-2 and bcl-X in bladder cancer.
    Kirsh EJ; Baunoch DA; Stadler WM
    J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
    Jahnson S; Karlsson MG
    J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.